Nanobiotix share falls to €25.96, breaking below support level
The Parisian biotech company specializing in nanomedical oncology is posting a significant decline this Thursday, in an SBF 120 index also declining. This movement extends a particularly weak monthly sequence, although the stock maintains an exceptional gain over twelve months.
A decline of nearly 6% that drives the stock below its three moving averages
Nanobiotix is down 5.94% to €25.96 in trading, ranking among the sharpest declines in the SBF 120 in an already weakening market (the index is down 1.25%). The price has fallen below its three moving averages: MA20 at €30.50, MA50 at €33.00 and MA200 at €28.63, representing respective gaps of -14.89%, -21.33% and -9.33%. The stock had already broken through its support level at €27.94 on Monday, September 28, and today's movement takes it even lower, to €25.96, beyond the previous threshold.
The RSI at 35 reflects persistent selling pressure without yet reaching outright oversold territory. Over the week, the decline reaches 14.15%, and over one month, losses exceed 25%.
Treasury of €110.9 million and a 55% annual gain in the backdrop
Despite this correction, Nanobiotix maintains a gain of 55.64% over twelve months, which contrasts with very negative monthly dynamics. The company published its first half 2026 results on September 24, reporting treasury of €110.9 million, compared to €52.8 million at the end of December 2025, following a capital increase of approximately €86 million completed in May 2026. This resource enables it, according to its statements at the time, to fund its operations through 2029.
The biotech is developing its radioamplifier NBTXR3 (JNJ-1900) in partnership with Johnson & Johnson. The nearest resistance level is located at €38.60, far from current levels.
